Know Cancer

forgot password

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen

Phase 2
18 Years
Not Enrolling
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer

Thank you

Trial Information

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination
with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in
Subjects with International Federation of Gynecology (FIGO) Stage IVB or Recurrent or
Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for
Advanced/Recurrent Disease

Inclusion Criteria:

- A subject will be eligible for inclusion in this study only if all of the following
criteria are met:

- Signed, written informed consent prior to performing any study-related procedures

- Female subjects ≥18 years of age

- FIGO Stage IVB, or recurrent or persistent cervical cancer

- Life expectancy of at least 12 weeks

- ECOG status of 0 or 1.

- Histologically confirmed FIGO Stage IVB, or recurrent or persistent squamous cell
carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not
amenable to curative treatment with surgery and/or radiation therapy

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20
mm when measured by conventional techniques, including palpitation, plain x-ray, CT
and MRI, or ≥10 mm when measured by spiral CT.

- At least one "target lesion" to be used to assess response as defined by Response
Evaluation Criteria in Solid Tumors (RECIST; Terasse, 2000). Tumors within a
previously irradiated field will be designated as "non-target" lesions unless
progression is documented or a biopsy is obtained to confirm persistence at least 90
days following completion of radiation therapy.

- Received 0 or 1 prior chemotherapy regimen for metastatic disease.

- Note: Chemotherapy given in combination with radiation therapy as a radiosensitizer
does not count toward this prior therapy limit

- Recovered from the effects of surgery or chemotherapy. At least three weeks must
have elapsed from the last administration of chemotherapy.

- Adequate organ and bone marrow function as defined in Table 1.

- Table 1:(Definitions for Adequate Organ Function)

- System:(Laboratory Values)

- Hematologic: Absolute neutrophil count (ANC)(≥ 1.5 X 109/L)Hemoglobin1(≥9
g/dL)Platelets(≥100 X 109/L)

- Hepatic: Total bilirubin (≤1.5 X ULN)AST and ALT (≤2.5 X ULN)

- Renal: Calculated creatinine clearance2 (≥50 mL/min)

- Urine protein3 (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined
by 24 hour urine protein analysis.)

- Subjects may not have had a transfusion within 7 days of screening assessment.

- Calculated by Cockcroft Gault formula See Appendix 7: Renal Function Tests

- A patient should first be screened with dipstick urinalysis. If urine protein by
dipstick analysis is ≥2+, then a 24-hour urine protein must be assessed and 24 hour
urine protein must be <1 g protein to be eligible.

- Ability to swallow and retain oral medication.

- A female is eligible to enter and participate in this study if she is of:

- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
including any female who has had:

- A hysterectomy

- A bilateral oophorectomy (ovariectomy)

- A bilateral tubal ligation

- Is post-menopausal (total cessation of menses for ≥ 1 year)

- Childbearing potential, has a negative serum pregnancy test within 2 weeks prior to
the first dose of study treatment, preferably as close to the first dose as possible,
and agrees to use adequate contraception. GSK acceptable contraceptive methods, when
used consistently and in accordance with both the product label and the instructions
of the physician, are as follows:

- An intrauterine device with a documented failure rate of less than 1% per year.

- Vasectomized partner who is sterile prior to the female subject's entry and is the
sole sexual partner for that female.

- Complete abstinence from sexual intercourse for 14 days before exposure to
investigation product, through the dosing period, and for at least 21 days after the
last dose of investigational product.

- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or
film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

Note: Oral contraceptives are not reliable due to potential drug-drug interactions.

- Subjects must provide written informed consent prior to performance of study specific
procedures or assessments, and must be willing to comply with treatment and follow-up
as outlined in the protocol. Procedures conducted as apart of routine clinical
management of the patient (e.g., blood count, imaging study) and obtained prior to
signed informed consent may be utilized for screening purposes provided these tests
are obtained as specified in the protocol

Exclusion Criteria:

- A subject will not be eligible for inclusion in this study if any of the following
criteria apply:

- Neuroendocrine or small cell carcinoma of the cervix.

- Prior use of any biologic therapy with VEGF, VEGFR, or ErbB1/ErbB2 inhibitors.

- Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,
biologic therapy, hormonal therapy, and tumor embolization).

- Concurrent treatment with an investigational agent or participation in another
clinical trial.

- Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever
is longer, preceding the first dose of study medication.

- Has taken or is taking prohibited medications listed in the protocol.

- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions
that could interfere with patient's safety, obtaining informed consent or compliance
to the study.

- History of another malignancy. Note: Patients who have had another malignancy and
have been disease-free for 5 years, or patients with a history of completely resected
non-melanomatous skin carcinoma or successfully treated in situ carcinoma are

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis. Routine screening with CNS imaging studies (computed
tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically

- Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach or small bowel.

- Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal
condition increasing the risk of perforation; history of abdominal fistula,
gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to
beginning therapy.

- Presence of uncontrolled infection.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib.

- Corrected QT interval (QTc) prolongation defined as QTc interval > 470 msecs.

- History of any one of the following cardiac conditions within the past 6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- History of cerebrovascular accident or pulmonary embolus within the past 6 months.

- Has Class III or IV heart failure as defined by the New York Heart Association (NYHA)
functional classification system (See Appendix 6)

- Poorly controlled hypertension (systolic blood pressure (SBP) of ≥ 140mmHg, or
diastolic blood pressure (DBP) of ≥ 90mmHg).

- Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior
to study entry. The blood pressure (BP) must be re-assessed on two occasions that are
separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments
must be < 140/90mmHg in order for a subject to be eligible for the study.

- History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf
vein thrombosis).

- Note: Patients with recent DVT who are treated with therapeutic anti-coagulant agents
(excluding therapeutic warfarin) for at least 6 weeks are eligible.

- Presence of any non-healing, non-tumor related wound, fracture, or ulcer, or the
presence of symptomatic peripheral vascular disease.

- Subjects with bilateral hydronephrosis which cannot be alleviated by ureteral stents
or percutaneous drainage.

- Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks
prior to beginning therapy, or anticipation of the need for a major surgical
procedure during the course of the study; minor surgical procedures such as fine
needle aspiration or core biopsy within 1 week prior to beginning therapy are also

- Unable to swallow and retain orally administered medication.

- Pregnant or lactating female.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free Survival (PFS) in Interim Analysis

Outcome Description:

PFS is defined as the interval between the date of randomization and the date of disease progression or death due to any cause. The study was designed to test Combination vs. Lapatinib first. The result indicated that Combination would not show improvement over Lapatinib even if followed until the final analysis and the Combination arm was terminated. The monotherapy arms continued to the final analysis. Data shown here are from this interim analysis.

Outcome Time Frame:

From randomization until at least 35 PFS events in pairwise comparison of the three treatment arms (Interim Analysis; up to 52.14 weeks)

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Spain: Ministry of Health

Study ID:




Start Date:

November 2006

Completion Date:

July 2011

Related Keywords:

  • Neoplasms, Uterine Cervix
  • Metastatic Cervical Cancer
  • pazopanib
  • ErB1/ErB2
  • lapatinib
  • persistent
  • VEGF
  • recurrent
  • metastatic cervical cancer
  • advanced
  • FIGO Stage IVB
  • Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms



GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Springfield, Massachusetts  01107
GSK Investigational Site Albuquerque, New Mexico  87109
GSK Investigational Site Akron, Ohio  44304
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Savannah, Georgia  31405
GSK Investigational Site Oklahoma City, Oklahoma  73112
GSK Investigational Site Germantown, Tennessee  38138
GSK Investigational Site New York, New York  10021